For the year ending 2025-12-31, DAWN made $158,182K in revenue. -$107,322K in net income. Net profit margin of -67.85%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Revenues | 158,182 | 131,161 | ||
| Cost of product revenue | 14,714 | 5,279 | ||
| Cost of license revenue | 2,496 | - | ||
| Research and development expense | 148,135 | 227,702 | ||
| Selling, general and administrative | 120,587 | 115,450 | ||
| Total cost and operating expenses | 285,932 | 348,431 | ||
| Loss from operations | -127,750 | -217,270 | ||
| Gain from sale of priority review voucher | 0 | 108,000 | ||
| Investment income, net | 18,471 | 19,701 | ||
| Other (expense) income, net | -19 | 1,217 | ||
| Total non-operating income, net | 18,452 | 128,918 | ||
| Loss before income taxes | -109,298 | 88,352 | ||
| Income tax benefit (expense) | -1,976 | 7,144 | ||
| Net loss | -107,322 | -95,496 | ||
| Basic EPS | -1.04 | -1.02 | ||
| Diluted EPS | -1.04 | -1.02 | ||
| Basic Average Shares | 103,205,703 | 93,234,195 | ||
| Diluted Average Shares | 103,205,703 | 93,234,195 | ||
Day One Biopharmaceuticals, Inc. (DAWN)
Day One Biopharmaceuticals, Inc. (DAWN)